Search research articles
Contact Us
Filters
Showing results (151-160 of 157) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 157 results.
JAMA
|
June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Jamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
The New England Journal of Medicine
|
June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Leukemia
|
January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
Jacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Blood
|
January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine
|
December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia
|
March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Blood
|
December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 157) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 157 results.
JAMA
|
June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Jamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
The New England Journal of Medicine
|
June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Leukemia
|
January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
Jacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Blood
|
January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine
|
December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia
|
March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Blood
|
December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Page
of 16